secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0001104659-23-083850
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q2 revenue $9.5M (+89% YoY); raises FY 2023 revenue guidance
-----------------------------------------------------------------

- Q2 total revenue $9.5M, +89% YoY; US HF revenue $8.3M, +119% YoY.
- Net loss $11.7M ($0.56 per share) vs $11.1M ($0.54 per share) in Q2 2022.
- Active US implanting centers grew to 140, up 97% from June 2022.
- FY 2023 revenue guidance raised to $37.0-38.5M (from $35.5-38.0M).
- PMA supplement filed with FDA for Barostim indication expansion in June 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923083850/0001104659-23-083850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923083850/tm2321888d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-083850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer